Crossmark

Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III–IVA esophageal squamous cell carcinoma post-surgery

Crossref DOI link: https://doi.org/10.1186/s13019-024-02500-9

Published Online: 2024-01-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Chunyang

Yu, Pengyi

Li, Hong

Yang, Xin

Wang, Jun

Jiang, Bo
Funding

Funding for this research was provided by:

Beijing Xisike Clinical Oncology Rresearch Foundation (Y-HH202101-0117)
License Information

Text and Data Mining valid from 2024-01-25

Version of Record valid from 2024-01-25
More Information

Article History

Received: 7 June 2023

Accepted: 14 January 2024

First Online: 25 January 2024

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by institutional/regional/national ethics/committee/ethics board of The First People’s Hospital of Chang-Zhou City, The Third Affiliated Hospital,Soochow University (2023005) and individual consent for this retrospective analysis was waived.

: All authors agree to participate and publish.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below